Flibanserin (Addyi) Switching Guide: Moving To and From Other HSDD Treatments

What Is Flibanserin and How Does It Work?

Flibanserin is a non-hormonal, centrally acting drug that targets the neurochemistry of sexual desire. It does not change hormones. Instead, it acts on three receptors simultaneously: it is a full agonist at serotonin 1A (5-HT1A) receptors, an antagonist at serotonin 2A (5-HT2A) receptors, and a weak agonist at dopamine D4 receptors 1. The net effect is a reduction in serotonergic inhibition of sexual desire circuits and a modest increase in dopaminergic and noradrenergic tone in the prefrontal cortex areas involved in sexual motivation.

This matters clinically because it explains both the drug's benefit and its risks. Serotonin suppresses desire; blocking 5-HT2A receptors lowers that brake. But the same serotonergic and dopaminergic activity in the brainstem creates sedation, dizziness, and the alcohol interaction that appears in the FDA REMS program 2.

Why the Mechanism Is Different From Everything Else in Sexual Medicine

No other approved HSDD drug works this way. Bremelanotide (Vyleesi), the only other FDA-approved option for premenopausal women, is a melanocortin receptor agonist given as a subcutaneous injection up to 45 minutes before anticipated sexual activity 3. Testosterone, used off-label in women, acts through androgen receptors. PDE5 inhibitors (sildenafil, tadalafil) target vascular smooth muscle. Flibanserin's CNS serotonin/dopamine mechanism is genuinely distinct, which means there is no pharmacological class overlap that forces a washout when you switch from bremelanotide or testosterone. The switching concern with flibanserin is almost entirely about its CYP3A4 and CYP2C19 metabolism and its CNS depressant profile, not receptor competition.

The Evidence Base for Efficacy

The BEGONIA trial, published in the Journal of Sexual Medicine in 2014, is the most-cited phase 3 study supporting flibanserin's approval 1. In BEGONIA, 1,090 premenopausal women with HSDD were randomized to flibanserin 100 mg at bedtime versus placebo for 24 weeks. The flibanserin group reported a mean increase of 2.5 satisfying sexual events (SSEs) per month compared with 1.5 in the placebo group. The drug also improved the Female Sexual Function Index desire domain score and reduced distress on the Female Sexual Distress Scale-Revised. The effect size is modest by most standards. Women considering switching to or from flibanserin should know the absolute benefit above placebo is roughly one additional satisfying event per month.

A practical way to frame the switching decision: flibanserin is your only option when you want a daily oral non-hormonal pill, you have primarily low desire (not arousal or pain), and you have the discipline to avoid alcohol most evenings. If any of those three conditions does not fit your life, an alternative or combination approach may perform better for you.

HSDD Treatment Options: Where Flibanserin Sits

Before discussing switching protocols, you need to understand the field of available treatments so the switch direction is clear.

FDA-Approved Drugs for HSDD in Women

| Drug | Mechanism | Route | Frequency | Approved population | |---|---|---|---|---| | Flibanserin (Addyi) | 5-HT1A agonist / 5-HT2A antagonist / D4 agonist | Oral tablet | Daily at bedtime | Premenopausal women | | Bremelanotide (Vyleesi) | Melanocortin MC4R agonist | SC injection | As-needed (max 1/24 h) | Premenopausal women |

Off-Label Options Commonly Used in Women

Testosterone (transdermal gel or cream, compounded) is the most studied off-label treatment for low sexual desire in women 4. A 2019 systematic review and meta-analysis in The Lancet found that transdermal testosterone significantly improved sexual function in postmenopausal women, but data in premenopausal women are considerably thinner 4. Ospemifene, approved for dyspareunia in menopause, and local estrogen products address arousal and pain more than desire and are not HSDD drugs per se.

Bupropion is sometimes used off-label when SSRI-induced sexual dysfunction is the primary driver of low desire. It has a different mechanism from flibanserin and no meaningful pharmacokinetic interaction that requires a washout between the two.

Switching Protocols: The Clinical Detail

Switching to or from flibanserin is not pharmacologically complex when you know two things: its metabolism pathway and its CNS depressant interactions. There is no published head-to-head switching trial comparing outcomes across these agents. The protocol below synthesizes FDA labeling, pharmacokinetic data, and clinical pharmacology principles.

Switching From Flibanserin to Bremelanotide

This is the most common switch direction in practice. Women who stop flibanserin because of the alcohol restriction, persistent dizziness, or inadequate response at 8 weeks can move to bremelanotide without a washout period. Flibanserin has a half-life of approximately 11 hours 2, meaning it is cleared to less than 2% of steady-state plasma concentration within 72 hours of the last dose. Because bremelanotide acts at melanocortin receptors with no serotonin or dopamine overlap, there is no pharmacodynamic reason to wait longer than three to four days after your last flibanserin tablet before using your first bremelanotide injection.

Practical steps:

1. Take your last flibanserin tablet at bedtime on day 1.
2. Wait a minimum of 72 hours (three full days).
3. Use bremelanotide 1.75 mg subcutaneously 45 minutes before the first anticipated sexual activity.
4. Assess nausea (the most common bremelanotide side effect, reported in approximately 40% of users) before deciding whether to continue 3.

Switching From Bremelanotide to Flibanserin

Bremelanotide has a half-life of approximately 2.7 hours and is largely eliminated within 24 hours of injection 3. You can start flibanserin the evening after your last bremelanotide dose. No washout is needed beyond one day of clearance.

Before starting flibanserin, your prescriber must review your full medication list for CYP3A4 inhibitors. Fluconazole, combined oral contraceptives, clarithromycin, and ketoconazole all inhibit CYP3A4 to varying degrees and can raise flibanserin blood levels dramatically. The FDA label reports that a single 200 mg dose of fluconazole raises flibanserin AUC by approximately 7-fold 2. Moderate CYP3A4 inhibitors (diltiazem, grapefruit juice consumed frequently) raise flibanserin exposure 2 to 3 times.

Switching From SSRIs or SNRIs to Flibanserin

This scenario comes up frequently because SSRIs and SNRIs themselves cause low sexual desire as a side effect. The pharmacodynamic concern here is additive serotonergic activity. Flibanserin's 5-HT1A agonism combined with an ongoing SSRI could theoretically increase serotonin syndrome risk, though this has not been reported in trials and the risk is considered low given flibanserin's presynaptic inhibitory mechanism. The more pressing concern is CYP2C19: fluoxetine and fluvoxamine are potent CYP2C19 inhibitors and also inhibit CYP3A4, substantially raising flibanserin plasma concentrations.

A clinically conservative approach:

• Taper the SSRI or SNRI to discontinuation under your prescriber's guidance.
• Allow five half-lives for clearance. For fluoxetine (and its active metabolite norfluoxetine), this means waiting four to six weeks after the last dose before starting flibanserin.
• For sertraline, escitalopram, and venlafaxine, clearance occurs within one to two weeks.
• Start flibanserin 100 mg at bedtime once SSRI clearance is confirmed and mood stability is assessed.

Switching From Testosterone to Flibanserin (or Adding Flibanserin)

Transdermal testosterone and flibanserin have no pharmacokinetic interaction. A woman who has been using compounded testosterone cream for low libido and has had partial response may add flibanserin without any washout or dose adjustment. The two agents address desire through entirely different pathways (androgen receptor signaling versus CNS serotonin/dopamine modulation), so combination use is not irrational, though no randomized trial has tested the combination in women. Be transparent with your prescriber so both drugs appear in your chart and neither is inadvertently discontinued when filling a prescription.

When Strong CYP3A4 Inhibitors Are Part of Your Regimen

This is the one switching scenario that genuinely prohibits starting flibanserin: if you are taking a strong CYP3A4 inhibitor that cannot be stopped (for example, ritonavir-boosted antiretroviral therapy, or a required antifungal course), flibanserin is contraindicated during that overlap 2. The plasma concentration rise is steep enough that the hypotension and CNS depression risk becomes clinically unacceptable.

Pregnancy, Lactation, and Contraception

This section is required reading if you are trying to conceive, pregnant, or breastfeeding.

Flibanserin is contraindicated in pregnancy. There are no adequate human studies in pregnant women. Animal data at doses producing plasma exposures similar to human therapeutic doses showed embryofetal toxicity in rats 2. Because HSDD is defined within the premenopausal population and many users are in their reproductive years, contraception planning is a direct clinical issue.

If You Are Trying to Conceive

Stop flibanserin before you begin attempting conception. With an 11-hour half-life, the drug clears within 72 hours of the last dose. A 72-hour stop is pharmacokinetically adequate, but most clinicians recommend stopping at least one full menstrual cycle before actively trying to conceive, to allow any theoretical fetal exposure window to close before implantation.

HSDD does not disappear during fertility treatment. If you are undergoing ovarian stimulation or IVF, which involves supraphysiologic estrogen levels and often significant psychological stress, low desire may worsen. Neither flibanserin nor bremelanotide has been studied in women undergoing assisted reproduction. Discuss management of HSDD symptoms with your reproductive endocrinologist, since behavioral and psychosexual approaches (couples therapy, mindfulness-based sex therapy) carry no fetal risk.

If You Are Pregnant

Stop flibanserin immediately. If you discover a pregnancy while taking flibanserin, call your prescriber. The drug clears within 72 hours. No registry data exist on first-trimester exposure in humans, so this should be reported to the Addyi pregnancy registry (Sprout Pharmaceuticals) and discussed with your OB.

Breastfeeding and Lactation

No published human data exist on flibanserin transfer into breast milk 2. Animal studies show flibanserin is present in rat milk. Given the drug's CNS activity and the absence of human lactation safety data, most clinicians recommend against using flibanserin while breastfeeding. The postpartum period, when HSDD may overlap with postpartum depression and low desire related to prolactin and estrogen suppression, is a time when non-pharmacologic approaches or, where appropriate, hormone evaluation, should be considered first.

Bremelanotide has similarly limited lactation data. Its short half-life (2.7 hours) means a "pump and dump" approach for 12 to 16 hours after a single injection is theoretically possible, but this has not been validated in lactation pharmacokinetic studies.

Contraception While on Flibanserin

Combined oral contraceptives (COCs) are moderate CYP3A4 inhibitors and raise flibanserin plasma levels. This does not mean you cannot use a COC while on flibanserin, but the combination requires prescriber awareness. Some women on COCs report more dizziness when flibanserin is added. Progestin-only pills, the hormonal IUD (levonorgestrel), and barrier methods do not inhibit CYP3A4 and do not interact pharmacokinetically with flibanserin.

Who This Is Right for (and Who It Is Not)

Premenopausal Women With Primary Low Desire

Flibanserin was studied in and approved specifically for premenopausal women with acquired, generalized HSDD. If you have had low sexual desire for at least six months, the desire is present across most sexual situations (not just one partner), the low desire is new compared with your earlier life, and it causes you personal distress, flibanserin fits its indication.

Women Who Cannot Drink Alcohol at Any Social Occasion

Flibanserin is genuinely difficult to use if your social or professional life involves evening alcohol. The REMS alcohol restriction is not a suggestion. A case-crossover pharmacology study showed that combining flibanserin with alcohol produces clinically meaningful hypotension and somnolence even at one to two standard drinks 2. If total alcohol avoidance on most evenings is not realistic for you, bremelanotide (used only before planned sexual activity) avoids this issue entirely.

Perimenopausal and Postmenopausal Women

Flibanserin is not FDA-approved for perimenopausal or postmenopausal women. The key trials enrolled premenopausal participants, and hormonal changes across the menopausal transition alter serotonergic tone in ways that may change the drug's effect and tolerability. The Menopause Society (formerly NAMS) notes that genitourinary syndrome of menopause (GSM), mood changes, and sleep disruption all contribute to low desire in midlife women and should be addressed before attributing HSDD to a purely neurochemical cause 5. Off-label use of flibanserin in postmenopausal women does occur clinically, but the evidence base is thin, and this should be described honestly to any woman in this life stage who asks.

Women With Liver Disease

Flibanserin is contraindicated in any degree of hepatic impairment. CYP3A4 and CYP2C19 are both hepatically expressed, and liver disease raises flibanserin exposure substantially.

Women on Psychiatric Medications

Women taking SSRIs for depression or anxiety, benzodiazepines for anxiety, or antipsychotics face layered interaction risks with flibanserin. Any CNS depressant adds to flibanserin's sedative effect. For women whose low desire is secondary to an SSRI, bupropion augmentation or switching the antidepressant to bupropion (which has neutral to positive sexual effects) may address desire without adding flibanserin's interaction burden.

Monitoring After a Switch

After switching to flibanserin from any prior treatment, the standard assessment window is eight weeks. Most trials, including BEGONIA, used at least eight weeks of treatment before evaluating SSE frequency. If you have not noticed any improvement in desire or distress after eight consistent weeks at 100 mg nightly, the standard recommendation is to discontinue flibanserin rather than dose-escalate (no higher dose has been studied or approved) 1.

Track these three outcomes yourself:

• Number of satisfying sexual events per four-week period (this is the primary endpoint from clinical trials and the most objective self-assessment).
• Score on the Female Sexual Distress Scale-Revised (FSDS-R); your clinician can provide the questionnaire.
• Side-effect burden: dizziness, somnolence, and nausea are the most common adverse events in trials, occurring in 11%, 11%, and 10% of flibanserin users respectively versus 2%, 4%, and 4% in placebo 1.

If side effects are the reason for the switch rather than inadequate efficacy, document them precisely. A woman who stopped flibanserin because of dizziness but had improved desire may benefit from a lower evening dose (50 mg is sometimes used off-label, though not formally studied for efficacy) rather than a full switch to an entirely different agent.

The Evidence Gap: What We Do Not Know

Women have historically been underrepresented in CNS drug trials, and HSDD research is no exception. Several evidence gaps matter for the switching decision:

• No head-to-head switching trial compares flibanserin to bremelanotide with patient-reported outcomes as the endpoint. The switch protocols described in this article are based on pharmacokinetic data and clinical pharmacology principles, not direct comparison trials.
• No published data exist on combination use of flibanserin plus bremelanotide. Some women and clinicians have combined daily flibanserin with as-needed bremelanotide, but there are no safety or efficacy data to guide this.
• Pharmacokinetic data in women across the menstrual cycle are absent. Estrogen and progesterone fluctuations affect CYP3A4 activity modestly; whether this changes flibanserin exposure meaningfully across cycle phases has not been studied.
• Black, Latina, and Asian women were underrepresented in BEGONIA and the other phase 3 trials 1. Pharmacogenomic differences in CYP3A4 and CYP2C19 expression by ancestry may affect both efficacy and side-effect burden, and this has not been formally evaluated.

When your prescriber is deciding whether to switch you to or from flibanserin, these gaps mean the decision should weight your personal side-effect experience and life circumstances heavily, because the trial data cannot always tell you what will happen for you specifically.

Practical Checklist Before Starting Flibanserin (or After Switching to It)

Review this with your prescriber:

• Full medication list reviewed for CYP3A4 and CYP2C19 inhibitors (including grapefruit juice, fluconazole, oral contraceptives, some antifungals, macrolide antibiotics).
• Liver function normal (hepatic impairment is a contraindication).
• Alcohol use honestly assessed and patient agrees to the REMS restriction.
• Not pregnant and reliable contraception in place if relevant.
• Baseline SSE count documented so you can track change at eight weeks.
• Bedtime dosing confirmed (not morning or afternoon; taking it at night limits hypotension/dizziness risk during waking hours).
• Plan to reassess at eight weeks with FSDS-R and SSE count.

The REMS program, Addyi REMS, requires prescribers to enroll and counsel on alcohol, hypotension, and CNS depression risks before prescribing 2. This is not optional paperwork; it is a legal condition of prescribing.